Prevalence Of Keratoconus Among Patients With Thyroid Gland Dysfunction

• Sponsor: Fayoum University (Other)
• Overall Status: Completed
• CT.gov ID: NCT04346992
• Collaborator: (none)
• Enrollment: 200
• Location: 1
• Actual Duration (Months): 12.1
• Patients Per Site Per Month: 16.5

Study Details

Study Description

Brief Summary

Hormonal imbalances are likely to affect the corneal metabolism and may be also associated with Keratoconus. Among the various endocrinologic dysfunctions assumed so far, thyroid gland dysfunction (TGD) (hypo- or hyperthyroidism; comprised as TGD) is frequently associated with eye diseases such as Graves disease

Condition or Disease	Intervention/Treatment	Phase
Keratoconus in Thyroid Gland Dysfunction	Other: no intervention

Detailed Description

Aim of the work

We aim to examine the prevalence of KC among patients already diagnosed by endocrinologist with TGD.

Materials and methods

Our Screening for KC will include evaluation of the demographic data and complete ophthalmological examination of the patients using:

VA Refraction K reading Slit lamp examination Pentacam Study design Epidemiological study

Inclusion citeria All patients diagnosed as thyroid gland dysfunction Control group

Exclusion criteria Uncooperative patients

Study Design

• Study Type: Observational
• Actual Enrollment: 200 participants
• Observational Model: Other
• Time Perspective: Prospective
• Official Title: Prevalence Of Keratoconus Among Patients With Thyroid Gland Dysfunction
• Actual Study Start Date: Apr 12, 2019
• Actual Primary Completion Date: Apr 15, 2020
• Actual Study Completion Date: Apr 15, 2020

Outcome Measures

Primary Outcome Measures

1. prevalence of keratoconus in thyroid gland dysfunction [we will recruit patients who meer the inclusion criteria during the study period April-August 2020]

   Our Screening for KC will include evaluation of the demographic data and complete ophthalmological examination of the patients using: VA Refraction K reading Slit lamp examination Pentacam

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 70 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• All patients diagnosed as thyroid gland dysfunction

Exclusion Criteria:

• Uncooperative patients

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Fayoum University	Fayoum		Egypt	63514

Sponsors and Collaborators

• Fayoum University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Omar Said, Dr, Fayoum University
• ClinicalTrials.gov Identifier: NCT04346992
• Other Study ID Numbers: R109
• First Posted: Apr 15, 2020
• Last Update Posted: Oct 14, 2020
• Last Verified: Oct 1, 2020

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Keratoconus; Thyroid Diseases

Study Results

No Results Posted as of Oct 14, 2020